IBRUTINIB by Novartis is small-molecule inhibitor of bruton’s tyrosine kinase (btk). Approved for older with chronic graft-versus-host disease (cgvhd) after failure of one, more lines of systemic therapy.
Drug data last refreshed 18h ago
small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in…
Worked on IBRUTINIB at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Remibrutinib Open Label Roll-over Post-trial Access Protocol
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Remibrutinib in Real-world Clinical Practice
Remibrutinib in Real-world Clinical Practice - a US Sub-study
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients